ERBB2 and neoplasm: By incorporating additional human tumor-associated antigens (e.g., B7-H3, EGFRvIII, GD2, and HER2), this model could strengthen multi-targeting approaches for pediatric diffuse gliomas by enabling preclinical development in an immunocompetent host.